Research Analysts Offer Predictions for Organogenesis Holdings Inc’s Q2 2019 Earnings (ORGO)

Organogenesis Holdings Inc (NASDAQ:ORGO) – Equities research analysts at Oppenheimer dropped their Q2 2019 EPS estimates for Organogenesis in a research report issued on Monday, May 13th. Oppenheimer analyst S. Lichtman now expects that the company will post earnings per share of ($0.13) for the quarter, down from their previous forecast of ($0.07). Oppenheimer currently has a “Outperform” rating and a $11.00 price target on the stock. Oppenheimer also issued estimates for Organogenesis’ Q3 2019 earnings at ($0.11) EPS, Q4 2019 earnings at ($0.06) EPS, FY2019 earnings at ($0.47) EPS, FY2020 earnings at ($0.38) EPS, FY2021 earnings at ($0.45) EPS and FY2022 earnings at ($0.20) EPS.

A number of other equities analysts have also weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of Organogenesis in a research report on Sunday, May 12th. Credit Suisse Group assumed coverage on shares of Organogenesis in a research report on Thursday, May 2nd. They issued an “outperform” rating and a $9.00 price objective for the company. CIBC initiated coverage on shares of Organogenesis in a research report on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, SunTrust Banks initiated coverage on shares of Organogenesis in a research report on Thursday, April 11th. They set a “buy” rating and a $11.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Organogenesis has an average rating of “Buy” and a consensus target price of $10.80.

NASDAQ:ORGO opened at $6.97 on Thursday. Organogenesis has a 1-year low of $6.28 and a 1-year high of $310.90.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The firm had revenue of $57.12 million for the quarter, compared to analyst estimates of $55.12 million.

A number of hedge funds have recently modified their holdings of ORGO. Morgan Stanley acquired a new position in Organogenesis during the first quarter worth approximately $30,000. Citigroup Inc. acquired a new position in Organogenesis during the first quarter worth approximately $41,000. Northern Trust Corp acquired a new position in Organogenesis during the first quarter worth approximately $131,000. California Public Employees Retirement System acquired a new position in Organogenesis during the first quarter worth approximately $202,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Organogenesis during the first quarter worth approximately $475,000. 0.08% of the stock is owned by hedge funds and other institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

See Also: How does inflation affect different investments?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.